Research and Development
Research and Development represents a true human and technological asset for Chiesi and, together with innovation, the driver of the company’s growth.
The company has been investing a significant portion of its turnover in Research & Development for many years. As a result of these investments, in 2025 the Group was ranked as the top pharmaceutical company in Italy for R&D investments and eleventh in Europe1.
In 2025, Chiesi filed 36 patent applications with the European Patent Office (EPO), reinforcing its position as the top Italian pharmaceutical company and seventh-ranked Italian companies across all sectors in terms of patents filings, with a total of 6,324 patents worldwide2.
Most of Chiesi’s medicinal products are the result of internal research, but the pipeline also includes products developed through collaborations and partnerships with other pharmaceutical companies.
The R&D team is primarily based at the Paolo Chiesi Research Center in Parma (Italy) and integrates with six other major research centers in Paris (France), Chippenham (UK), Cary (USA), Lidingo (Sweden), Shanghai (China), and Toronto (Canada).
The number of Research and Development programs continues to increase and diversify, enriching the therapeutic offering. It focuses on several key areas: chronic respiratory diseases, rare and ultra‑rare diseases, neonatology, and special care.
We concentrate both on development (clinical research aimed at registering new medicines) and on applied research (identifying new chemical or biological entities, or different therapeutic solutions).
Chiesi is expanding its product portfolio with various types of medicines alongside traditional small molecules, such as biological products (proteins) and advanced therapies (cell therapies), while consistently embracing an innovative approach to these emerging therapeutic areas.
- European Commission, Joint Research Centre, EU Industrial R&D Scoreboard 2024
- European Patent Office, 2025 Report
Other documents